Chelsie Derman

A study showed age and sex perform better at identifying the risk for opioid use disorder than candidate genetic variants.

Subjective poor sleep quality is tied to greater systolic blood pressure in adults ≤ 49 years with optimal sleep duration, compared with adults ≥ 50 years.

A study found many people with dementia live approximately 1 third of their remaining life expectancy in nursing homes.

In a recent study, participants reported worse patient care experience and staff responsiveness following the private equity acquisition of hospitals.

HCPLive spoke with John M. Kane, MD, about phase 2 LB-102 data for schizophrenia.

A new study found that depression prevalence among older adults was greater for those who were 65 – 69 years old.

SP-624, a SIRT6 activator, showed promise in an exploratory study for treating depression and cognition in females with MDD. Positive EEG data suggests enhanced neural connectivity.

New research reveals that frequent social media use, especially active use of platforms such as TikTok and Facebook, is linked to greater irritability levels.

A recent study showed expression profiles of amacrine cells, the interneurons within the retina, were enriched in schizophrenia genetic risk factors.

Individuals with stable schizophrenia struggle to recognize facial emotions such as sadness, disgust, and anger—but not happiness—which may impact social interactions.

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.

Participants with greater vitamin D levels had a 16% lower migraine prevalence than those with lower vitamin D levels.

Glutamatergic medications show promise for OCD & related disorders, reducing Y-BOCS scores.

A study found that the protein ADM significantly mediates loneliness' link to cardiovascular disease, stroke, dementia, and mortality, emphasizing loneliness’ health risks.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

This Psychiatry Month in Review features promising phase 3 data, what is moving in the pipeline, and where the psychiatry field is heading into 2025.

A study found that NT-proBNP levels predict cardiovascular and renal risks in patients with advanced CKD and anemia. Greater NT-proBNP variability showed increased renal risks.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

From FDA approvals to updated guidelines, 2024 brought transformative advancements in sleep medicine, offering new hope for managing complex sleep disorders.

Atogepant 60 mg, an oral CGRP receptor antagonist, demonstrated rapid and effective migraine prevention, reducing frequency and improving function in 4 weeks.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.

In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.